Anticardiac Antibodies in Patients with Chronic Pericardial Effusion

Table 3

Clinical features and antimyolemmal and antifibrillary antibodies in patients with and without recurrence of pericardial effusion.

	Patients with recurrence ()	Patients without recurrence ()	value
Age (years)	58,71 ± 17,01	55,43 ± 16,13	NS
Female/male	11/6	4/9	NS
Pericardial effusion (mL)	366,18 ± 389,81	490 ± 427,79	NS
AMLAs in PF	1,55 ± 0,66	1,65 ± 0,43	NS
AMLAs in SE	2,24 ± 0,31	1,96 ± 0,32	0,03
AFAs in PF	1,56 ± 0,58	1,62 ± 0,42	NS
AFAs in SE	2,09 ± 0,26	1,96 ± 0,32	NS

NS: nonsignificant.